Page last updated: 2024-10-30

lansoprazole and Hypokalemia

lansoprazole has been researched along with Hypokalemia in 1 studies

Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.

Hypokalemia: Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Eiro, M1
Katoh, T1
Watanabe, T1

Other Studies

1 other study available for lansoprazole and Hypokalemia

ArticleYear
Use of a proton-pump inhibitor for metabolic disturbances associated with anorexia nervosa.
    The New England journal of medicine, 2002, Jan-10, Volume: 346, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alkalosis; Anorexia Nervosa; Bicarbonates; Bulimia;

2002